{"id":130706,"date":"2026-07-07T11:04:08","date_gmt":"2026-07-07T17:04:08","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=130706"},"modified":"2026-07-07T11:04:08","modified_gmt":"2026-07-07T17:04:08","slug":"whats-coming-after-ozempic-and-zepbound-the-2026-weight-loss-drug-pipeline","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/whats-coming-after-ozempic-and-zepbound-the-2026-weight-loss-drug-pipeline\/","title":{"rendered":"What’s Coming After Ozempic and Zepbound: The 2026 Weight Loss Drug Pipeline"},"content":{"rendered":"

The obesity drug pipeline in 2026 is the most active it has ever been, with several new medications either just approved or moving through late-stage trials. The short version: an oral GLP-1 pill (orforglipron, branded Foundayo) reached the market in early 2026, a triple agonist (retatrutide) is posting the largest weight loss ever seen in trials, and combination and dual-hormone drugs like CagriSema and survodutide are advancing toward possible approval. Ozempic and Zepbound aren’t going anywhere, but they now sit at the front of a rapidly growing lineup. Here’s a clear map of what’s arriving and what’s still on the way.<\/p>\n

Already here: the oral pill era begins<\/h3>\n

The biggest 2026 milestone is the arrival of effective GLP-1 pills. Orforglipron (Foundayo) was FDA approved in April 2026 as a once-daily tablet that can be taken any time without food or water rules, producing about 11% to 12% weight loss at its highest dose in trials. It followed an oral form of semaglutide approved in late 2025. For people who prefer to avoid injections, this is a meaningful shift.<\/p>\n

The headliner: retatrutide<\/h3>\n

The drug generating the most attention is retatrutide, Eli Lilly’s investigational triple agonist that activates GLP-1, GIP, and glucagon receptors. Its efficacy case began with a phase 2 trial published in the New England Journal of Medicine in 2023<\/a> showing about 24% weight loss, and its 2026 phase 3 topline reported roughly 28% at the highest dose, the largest figure in a phase 3 obesity trial to date. It’s still in trials, with an FDA filing generally expected in late 2026 or early 2027.<\/p>\n

The combinations and dual agonists<\/h3>\n

Two other approaches are advancing toward possible approval:<\/p>\n

CagriSema (Novo Nordisk) combines semaglutide with cagrilintide, an amylin analog, and produced about 20% weight loss in trials. Novo Nordisk filed for approval in late 2025, with a decision anticipated in late 2026.<\/p>\n

Survodutide (Boehringer Ingelheim) is a GLP-1\/glucagon dual agonist that produced up to about 16.6% weight loss and shows a distinct benefit for liver fat, making it a leading candidate for the fatty liver disease MASH. It’s in phase 3 trials.<\/p>\n

The next wave<\/h3>\n

Further back in development, several more candidates are worth knowing about:<\/p>\n

\n\n\n\n\n\n\n\n\n\n
Drug<\/th>\nType<\/th>\nRoute<\/th>\nStatus<\/th>\n<\/tr>\n<\/thead>\n
Retatrutide<\/td>\nTriple agonist<\/td>\nInjection<\/td>\nPhase 3<\/td>\n<\/tr>\n
CagriSema<\/td>\nAmylin + GLP-1<\/td>\nInjection<\/td>\nFDA review<\/td>\n<\/tr>\n
Survodutide<\/td>\nGlucagon + GLP-1<\/td>\nInjection<\/td>\nPhase 3<\/td>\n<\/tr>\n
Amycretin<\/td>\nAmylin + GLP-1<\/td>\nPill or injection<\/td>\nEntering phase 3<\/td>\n<\/tr>\n
Orforglipron (Foundayo)<\/td>\nOral GLP-1<\/td>\nPill<\/td>\nApproved 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Amycretin (Novo Nordisk) is especially interesting because it combines amylin and GLP-1 in a single molecule available as both a pill and an injection, and it’s moving into phase 3 in 2026. Other names circulating in earlier research include additional oral pills and next-generation combinations, though most are further from the finish line.<\/p>\n

What this means for you<\/h3>\n

Consider a hypothetical patient reading the headlines and wondering whether to wait for the “best” drug. Here’s the practical reality: the pipeline is exciting, but most of these are a year or more from availability, and some may not be approved at all. Meanwhile, the medications already on the market produce substantial, well-documented weight loss. Waiting for a future drug means going untreated now, which carries its own costs.<\/p>\n

Common questions<\/h3>\n

What’s the strongest weight loss drug coming?<\/h4>\n

On trial data, retatrutide has produced the largest weight loss, up to roughly 28% to 30%. It’s still investigational and not yet available.<\/p>\n

Is there a weight loss pill now?<\/h4>\n

Yes. Oral semaglutide and orforglipron (Foundayo) are both FDA-approved GLP-1 pills as of 2025 and 2026, respectively.<\/p>\n

Should I wait for the newer drugs?<\/h4>\n

Waiting means staying untreated in the meantime. Many people benefit from starting a proven, available option now and revisiting newer drugs with their provider later.<\/p>\n

The bottom line<\/h3>\n

The 2026 pipeline is delivering more options, from oral pills that are already here to triple agonists on the horizon. But you don’t have to wait to make progress. You can see which available treatments fit you through TrimRx’s quiz<\/a> and get guidance from a licensed provider. You can also learn more about the TrimRx program<\/a>.<\/p>\n

This information is for educational purposes and is not medical advice. Several drugs mentioned are investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

The obesity drug pipeline in 2026 is the most active it has ever been, with several new medications either just approved or moving through…<\/p>\n","protected":false},"author":7,"featured_media":51809,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[14],"tags":[],"class_list":["post-130706","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-zepbound"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=130706"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130706\/revisions"}],"predecessor-version":[{"id":130707,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/130706\/revisions\/130707"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/51809"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=130706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=130706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=130706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}